glp-1 drug exposure pharmaceutical companies 2025 2025’s Breakthrough Obesity Treatments: Top & Innovations What's next for GLP-1 innovation:
Description
For a deeper dive into these topics, watch the webinar on-demand here.
Also, retatrutide isn't FDA-approved, while Ozempic and Mounjaro are, so "better" depends on whether you prioritize efficacy or regulatory approval and availability
Not every Medicare Advantage plan includes Part D drug coverage, but many do
For context, CagriSema's GI rate was compared to its individual components: semaglutide alone and cagrilintide alone both had lower GI event rates than the combination, consistent with additive GI effects
doi: 10.1111/obr.13370
use of gastric ultrasound to assess residual volume before surgery
